Anti-Infectives
Colistin i.v. effective for control of multiresistant Gram-negative pathogens
Published in Drug Week, October 14th, 2005
"Colistin, an antibiotic almost abandoned for intravenous administration for many years due to its reported toxicity, has been recently reintroduced in clinical practice due to the emergence of multidrug-resistant Gram-negative bacteria and the lack of development of new antibiotics to combat them," physicians in Greece explained.
"To assess the safety and effectiveness of intravenous colistin, in combination with other antimicrobial agents, in the treatment of serious infections in patients without cystic fibrosis, a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-10-14)
More Articles from Drug Week
- Cancer Therapy
Aplidin combination trials initiated for metastatic malignant melanoma - Drug Development
Phase III trial initiated to evaluate anemia treatment in heart failure patients - Pain Management
Positive phase III clinical results for Remoxy reported - Pain Management
Statistically significant analgesic effects of bicifadine in phase III announced - Addiction Medicine
Mu agonist efficacy affects LAAM, buprenorphine cross-tolerance - Adverse Drug Reaction
Australian Agency urges caution over Paroxetine during pregnancy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
